Affimed Therapeutics AG expands clinical development team

Heidelberg, Germany — March 08, 2010 — In preparation for the clinical entry of its first product candidate Affimed Therapeutics AG, the therapeutic TandAb antibody company with innovative methods of treatment against life-threatening diseases expands its development team with an experienced expert.

Effective immediately, Dr Christian Hucke takes over responsibility for planning and implementation of the clinical development programs at Affimed. Dr Hucke joins Affimed from Grünenthal GmbH.

Christian Hucke has long-term experience in conception and management of clinical studies. At Grünenthal he had the overall responsibility for a worldwide Phase-III-Study in pain therapy of cancer patients as well as a Proof-of-Concept-Phase-II-Study against diabetic polyneuropathy. Previously, Dr Hucke worked in clinical drug development at PAION Deutschland GmbH and the ClinPharmCologne TROPON GmbH. In the course of his various activities he was responsible for more than 12 Phase-I, II- and III-Studies in diverse indications. Christian Hucke is a doctor in biology with focus on immunology. After graduating and obtaining a doctorate degree in Düsseldorf he worked at the institute of Medical Microbiology at the Heinrich-Heine University of Düsseldorf.

Dr Rolf H. Günther, CEO of Affimed, commented: “The year 2010 will be a very important and decisive year for Affimed: both our lead-products will enter the clinic in 2010. In this crucial phase, Christian Hucke will hold a key position in our development team.”

Dr Christian Hucke added: “I am looking forward to this challenging task in an innovative company. With its unique TandAb platform Affimed set standards for the development of new antibody therapeutics. It is a special challenge to be involved in the clinical development from the very beginning.”

About Affimed Therapeutics AG

Affimed Therapeutics AG is a therapeutic antibody company developing unique antibody therapeutics as novel treatments for life threatening diseases with high unmet medical need. The company has been generating a growing pipeline of anticancer drug candidates based on its proprietary TandAb technology platform. Affimed’s lead product candidate AFM13 for the treatment of Hodgkin’s disease has successfully completed preclinical development and will enter clinical studies in early 2010. Both AFM11 and AFM12 to treat Non-Hodgkin’s lymphoma are currently in preclinical development and are expected to begin clinical studies in late 2010. Further novel product candidates are being developed for the treatment of solid tumors, autoimmune diseases and asthma. Affimed’s proprietary and highly productive TandAb technology enables the company to generate unique tetravalent, bispecific, fully human antibody formats that promise increased therapeutic potential and superior profiles compared to monoclonal antibodies. The private company Affimed, which employs 26 people in Heidelberg, is a spin-off from the German Cancer Research Centre (DKFZ), Heidelberg.